自体外周血干细胞（PBSC）移植在儿科癌症治疗中至关重要，串联移植对某些恶性肿瘤有益。收集低体重儿童的 PBSC 具有挑战性。我们回顾性分析了在我院接受自体 PBSC 采集的体重 <15 kg 的儿童癌症患者的数据。在儿科重症监护病房连续 2 或 3 天进行收集，以收获足够的干细胞（目标 ≥2 × 106 CD34 细胞/千克/单采血液成分）。从2006年4月到2021年8月，我们对40名患者进行了50次动员后进行了129次采集，中位年龄为1.9（范围，0.6-5.6）岁，体重为11.0（范围，6.6-14.7）kg。每个单采血液中的中值 CD34 细胞为 4.2（范围，0.01-40.13）× 106/kg。 78% 和 56% 的动员分别达到了单次或串联移植所需的足够细胞剂量，无需额外等分。单采前造血祖细胞 (HPC) 计数与单采液中 CD34 细胞产量高度相关 (r = 0.555，P < 0.001)。即使没有辐射暴露，单独使用粒细胞集落刺激因子对于 2 岁以上儿童的动员也无效。通过结合血浆分离前 HPC 计数≥20/μL 和 3 个显着宿主因素，包括年龄 <2 岁、未接受放射线照射和使用化疗，目标实现的预测率有所提高（曲线下面积 0.787）。版权所有 © 2024国际细胞学会

Autologous peripheral blood stem cell (PBSC) transplantation is crucial in pediatric cancer treatment, and tandem transplantation is beneficial in certain malignancies. Collecting PBSCs in small children with low body weight is challenging. We retrospectively analyzed data of pediatric cancer patients weighing <15 kg who underwent autologous PBSC harvesting in our hospital. Collections were performed in the pediatric intensive care unit over 2 or 3 consecutive days, to harvest sufficient stem cells (goal ≥2 × 106 CD34+ cells/kg per apheresate). From April 2006 to August 2021, we performed 129 collections after 50 mobilizations in 40 patients, with a median age of 1.9 (range, 0.6-5.6) years and a body weight of 11.0 (range, 6.6-14.7) kg. The median CD34+ cells in each apheresate were 4.2 (range, 0.01-40.13) × 106/kg. 78% and 56% of mobilizations achieved sufficient cell dose for single or tandem transplantation, respectively, without additional aliquoting. The preapheresis hematopoietic progenitor cell (HPC) count was highly correlated with the CD34+ cell yield in the apheresate (r = 0.555, P < 0.001). Granulocyte colony-stimulating factor alone was not effective for mobilization in children ≥2 years of age, even without radiation exposure. By combining the preapheresis HPC count ≥20/μL and the 3 significant host factors, including age <2 years, no radiation exposure and use of chemotherapy, the prediction rate of goal achievement was increased (area under the curve 0.787).Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.